Exploring New Frontiers: Innovations and Therapeutic Targets in Dermatology
Author:
Affiliation:
1. Dermatology Service, Hospital Universitario Ramón y Cajal, Irycis, 28034 Madrid, Spain
2. Internal Service, Hospital Universitario Ramón y Cajal, Irycis, 28034 Madrid, Spain
Abstract
Publisher
MDPI AG
Link
https://www.mdpi.com/1422-0067/25/15/8102/pdf
Reference11 articles.
1. The potential of RNA therapeutics in dermatology;Chai;Ann. Acad. Med. Singap.,2024
2. Jin, S., Wan, S., Xiong, R., Li, Y., Dong, T., and Guan, C. (2024). The role of regulatory T cells in vitiligo and therapeutic advances: A mini-review. Inflamm. Res., 1–22.
3. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: A post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials;Bruce;Lancet Rheumatol.,2022
4. EMSED (Etude des maladies systémiques en dermatologie) study group. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus;Chasset;J. Am. Acad. Dermatol.,2023
5. Successful treatment of erythema nodosum leprosum with upadacitinib and roflumilast;Int. J. Dermatol.,2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3